1. Pink Sheet
  2. >>Market Access

A Quick Metric for Measuring Pharma's Success in Healthcare Reform

 
• By Cole Werble

Pharma is looking at some very achievable business targets from the pending health care reform legislation. It’s not going to take too many new scripts from the people who currently do not have insurance for pharma to get a return from the new tax and rebate payments that are part of its support for ObamaCare.

The question of how much the pharmaceutical industry stands to gain or lose form health care reform legislation is difficult to get your arms around. Even the most common headline numbers, like the $80 billion commitment from pharma to pay for health reform, are more a part of the political process than firm expenditure estimates.

Here's a simpler metric to judge what health reform means to pharma: four extra monthly prescriptions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.